07/09/2015 - Press release
The CARDIoGRAMplusC4D Consortium, an international project in which researchers from theIMIM (Hospital del Mar Medial Research Institute) participated as the only Spanish participants, has identified 58 DNA loci or regions, 10 of which are new, linked to the risk of experiencing an ischemic heart disease. These 58 loci, besides confirming the relevance of controlling cholesterol levels and inflammation, identify in a novel way the relevance of the functioning of the arterial wall in the origin of this disease. The study is published in the prestigious journal Nature Genetics and is the first to have systematically analysed 2.7 million rare genetic characteristics. Ischemic heart disease is the leading cause of death in industrialised countries and can appear as an angina pectoris, a myocardial infarction and, sometimes, as sudden death. It is known that genetic factors account for 40 to 50% of the risk of suffering the disease, and this explains why great efforts are being invested to identify the genetic characteristics associated to this pathology, after 48 genetic characteristics have been identified in previous studies, some of which by this same research group.
Més informació "New clues on the genetic basis of myocardial infarction"
29/06/2015 - Institutional news
Dated June 2015, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM) has been recognized by the European Commission with the “HR Excellence in Research” award. This recognition highlights IMIM’s commitment towards adopting the general principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers (Charter&Code) and gives its full support to the improvement of human resources internal policies and procedures. This recognition of excellence is an opportunity to establish a global and cohesive human resources strategy which will allow for an international visibility provided by a stimulating work environment and favorable working conditions for research.
18/05/2015 - Press release
Under Horizon 2020, the EU has funded the 3.5 million project MedBioinformatics. This project aims to develop useful bioinformatics tools and applications, and autonomously usable for analysing the huge amount of data and knowledge generated in healthcare and biomedical research in order to facilitate translational research and precision medicine.The Hospital del Mar Medical Research Institute of Barcelona (IMIM) coordinates the EU-funded MedBioinformatics research project. According to Prof. Ferran Sanz, director of the IMIM-UPF Research Programme on Biomedical Informatics (GRIB) and coordinator of this project, "most potential users, i.e. translational researchers and health professionals, do not have adequate tools to efficiently exploit this large and heterogeneous amount of information. So far, efforts to develop bioinformatics methods and tools have not produced the expected impact in healthcare environments"
13/05/2015 - Press release
Researchers from the Hospital del Mar Medical Research Institute (IMIM) have discovered the key role of an enzyme in the differentiation ability of embryonic stem cells. According to the study published in the journal Molecular Cell, enzyme LOXL2 would be involved in maintaining the balance between the pluripotency and the differentiation in this type of cells that can turn into any cell in the body. The study was coordinated by the researcher from the Cancer Research Programme Sandra Peiró, and explores in greater depth the knowledge on the specialization mechanism of embryonic stem cells, opening the door to a better manipulation. Researchers from the Experimental and Health Sciences Department at the Universitat Pompeu Fabra also participated in the study.
Més informació "Key role of enzyme in the pluripotency of embryonic stem cells discovered"
28/04/2015 - Press release
Chemotargets, a spin-off company of IMIM, has launched CTlink[GUI] - a commercial version of the CTlink software that offers users intuitive, interactive graphical tools enabling them to more easily analyse results obtained using this software. CTlink can be installed on any Linux, Windows or Mac computer, desktop or laptop, and can predict how a small molecule will interact with thousands of different proteins. It is designed as a computational framework for linking different systemic entities - that is, for linking molecules, proteins, pathways, side effects, organs and diseases. It is a very important tool used by biotechnology and pharmaceutical companies.
Més informació "Chemotargets launches easier-to-use, more intuitive graphical interface CTlink[GUI]"
21/04/2015 - Press release
Researchers at the Institut Hospital del Mar d’Investigacions Mèdiques (IMIM) have identified a new way of treating colorectal cancer. In the study published in the journal Science Signaling, the team led by LLuís Espinosa, investigator of IMIM's research group into stem cells and cancer, have shown that inhibition of endosomal activity is a potential therapeutic strategy for the treatment of cancers with the BRAF mutated gene. This discovery is an important step in the personalisation of the treatment of colorectal cancer, as the presence of this mutation is associated with an increased resistance compared to standard therapies. Researchers from IDIBELL - the Catalan Institute of Oncology - and the Hospital de Bellvitge also participated.
19/02/2015 - Press release
Researchers at IMIM (Hospital del Mar Medical Research Institute) have applied a new computational methodology to anticipate the degree of selectivity of the molecules that are used to study protein functions and reduce the risk of establishing erroneous relations between proteins and diseases. The proteins under study could be future candidates for new therapeutic targets. The study is published in the prestigious journal ACS Chemical Biology and was selected for the cover. Molecules are essential tools for exploring protein functions, as they have the capacity to activate, inhibit and modulate their function. For many years, in order to explore protein functions, namely to know their biological role, small molecules known as 'chemical probes' have been used, which interact with the protein under study, to become a possible candidate as a new therapeutic target. However, in order for them to be truly useful, these molecules must selectively interact with the protein under study. ‘Until now, it was assumed that these chemical probes only and exclusively interacted with the protein that was being studied, so that any variations in the results of experiments were interpreted as the consequence of the selective interaction of the chemical probe with the protein under study’ comments Jordi Mestres, coordinator of the Research Group in Systems Pharmacology at the Research Programme on Biomedical Informatics (GRIB per its Spanish acronym) at IMIM and the UPF.
Més informació "The promiscuity of chemical probes discovered"
28/01/2015 - General information
The project iPIE: Intelligence Led Assessment of Pharmaceuticals in the Environment starts on February 2015 with a kick off meeting at Barcelona Biomedical Research Park (PRBB) and the participation of the GRIB research groups of Integrative Biomedical Informatics (IBI) and PharmacoInformatics (PhI) of Institut Hospital del Mar d’Investigacions Mèdiques (IMIM)) and Pompeu Fabra University (UPF). It is often ignored that any drug administered to human patients ends up in the environment, either in the original form or as a mixture of drug metabolites. Testing the environmental impact of novel drug candidates is therefore important in order to early discard potentially dangerous ones. With a budget of 10.2 million euros and a duration of 4 years, the project iPIE aims to develop a predictive framework that utilise existing information and in silico models to support more intelligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for full environmental risk assessment and/or environmental (bio) monitoring.
Més informació "Project iPIE: Testing the environmental impact of drugs"
17/12/2014 - Institutional news
As of January 1st, Dr. Rosa Ventura will be the new director of the Anti-Doping Control Laboratory at IMIM, replacing Dr. Jordi Segura who, after 30 years, is leaving the post to retire. However, until July 2016, Dr. Segura will remain at the Laboratory part-time supporting research and any other need that may arise. Since 1985, when the Laboratory gained accreditation from the International Olympic Committee (IOC), and later on from the World Anti-Doping Agency (WADA), Dr. Segura has been at the helm of the Laboratory, with a clear priority right from the start, that is to high quality and reliable services. A Laboratory that has been in charge of controls for important sports events such as the Barcelona Olympics and Paralympics in 1992; the Pan American Games in Havana in 1991; in Mar de Plata in 1995 and Mexico 2011; The Asian Games in Bangkok in 1998, or the FINA World Swimming Championships held in Barcelona in 2003 and 2013, as some of the most relevant ones. The Lab also collaborated in anti-doping controls for the Olympics during the past 25 years.
Més informació "Rosa Ventura is the new director of the Anti-Doping Control Laboratory at IMIM"
2/12/2014 - Press release
With the goal of promoting the safety of patients and the quality of healthcare in Europe, the European Commission, sponsored by the Italian Presidency, has organised a meeting in Rome on 2nd and 3rd December with the participation of healthcare experts, researchers, politicians and international journalists, to discuss, from different perspectives, how to promote the quality of medical healthcare through healthcare systems and how to improve security in hospitals. IMIM’s project is the only one selected from Spain. The meeting will focus on communicating the results of some projects funded through the EU Healthcare Programme and the impact on the daily lives of Europeans. From all projects submitted, only 8 have been selected in several areas, one of them being the EURHOBOP Project (EURopean Hospital Benchmarking by Outcomes in acute coronary syndrome Processes), coordinated by Dr. Jaume Marrugat, a researcher from the research group on cardiovascular epidemiology and genetics at IMIM (Hospital del Mar Medical Research Institute).
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
